A Leader’s Guide to Evaluating Metabolic Health Solutions

Research Spotlight - Virta Metabolic Disease

Research Spotlight | Union Health Benefits

Rising rates of obesity, type 2 diabetes, cardiovascular disease, and other metabolic conditions are placing growing pressure on union health and welfare funds. At the same time, increased demand for GLP-1 medications has created new clinical, financial, and benefit-design questions for trustees, fund administrators, consultants, and other union benefits decision-makers.

How can a health plan improve outcomes without relying on medication alone? What evidence should trustees request from prospective metabolic health partners? How should a fund evaluate GLP-1 utilization, member support, long-term results, and return on investment?

Virta Health’s new white paper, A Leader’s Guide to Metabolic Disease Reversal Solutions, examines these questions and provides a practical framework for employers and health plans evaluating metabolic health programs.

Why This Research Matters to Union Health Plans

Metabolic health is not a single-condition issue. Obesity, type 2 diabetes, cardiovascular disease, kidney disease, and other chronic conditions can affect members’ health while contributing to medical claims, prescription expenses, disability, absenteeism, and other costs.

For Taft-Hartley funds and multi-employer health plans, these challenges are compounded by the need to serve diverse member populations while protecting the long-term sustainability of collectively funded benefits.

GLP-1 medications have added another layer to that responsibility. Although these medications can be effective for some members, plans must consider more than prescription access. Benefits leaders also need to evaluate:

  • Appropriate clinical oversight
  • Medication utilization and affordability
  • Member adherence and discontinuation
  • Nutritional and behavioral support
  • Long-term weight and metabolic outcomes
  • Opportunities to reduce medication use when clinically appropriate
  • Measurable medical and pharmacy savings

Virta’s guide encourages benefits leaders to examine whether their current strategy is managing individual conditions or addressing the underlying metabolic health needs that can contribute to multiple chronic conditions.

What Union Benefits Leaders Will Learn

How metabolic disease affects healthcare spending

The guide explores the relationship between poor metabolic health and several of the conditions driving employer and health plan costs. It also discusses the potential financial consequences of continuing with fragmented programs that address obesity, diabetes, cardiovascular disease, and related conditions separately.

How common metabolic health solutions compare

Readers will find a high-level comparison of several approaches, including:

  • Diabetes management programs
  • Weight and condition management programs
  • Bariatric surgery
  • GLP-1 medications
  • Metabolic disease reversal programs

The guide compares these approaches through the lens of cost, clinical outcomes, medication use, and the ability to support sustainable health improvements.

What role GLP-1 medications can play

The white paper does not dismiss GLP-1 medications. Instead, it presents them as one potential clinical tool within a broader metabolic health strategy.

Virta recommends that health plans consider three distinct pathways:

  1. An effective option for members who do not use or do not want medication
  2. Nutritional and behavioral support for members who use GLP-1 medications
  3. A clinically supervised path for members who may eventually reduce or discontinue medication when appropriate

The guide also discusses the importance of provider oversight, responsible prescribing, deprescribing protocols, and strategies for helping members maintain their progress if medication use ends.

How to evaluate a metabolic health partner

One of the guide’s most useful sections for union trustees and fund administrators is a detailed list of questions to incorporate into vendor demonstrations or requests for proposals.

The questions address:

  • Reversal Capabilities
  • GLP-1 Strategies
  • Outcomes and ROI
  • Commitment to equitable, inclusive care
  • Ease of implementation 
  • Product innovation and enhancements 

These questions can help a fund look beyond sales presentations and compare prospective partners using consistent clinical, financial, and operational criteria.

Questions Trustees Should Ask Before Selecting a Solution

Before choosing a metabolic health partner, union benefits leaders should ask:

  • Are the vendor’s outcomes supported by peer-reviewed research?
  • Were the findings independently validated?
  • How large and diverse were the populations studied?
  • Are savings based on actual claims or financial models?
  • Does the program charge for members who disengage?
  • What clinical oversight is provided?
  • How does the program support members using GLP-1 medications?
  • What happens when a member stops taking a GLP-1?
  • Can the vendor demonstrate sustained results over multiple years?
  • Are fees or performance guarantees tied to measurable outcomes?

Trustees should also distinguish between independent evidence, peer-reviewed research, modeled projections, internal company analyses, and member testimonials when reviewing a vendor’s claims.

Read the Complete White Paper

A Leader’s Guide to Metabolic Disease Reversal Solutions provides a practical starting point for union health plans reviewing their metabolic health strategy or preparing for a vendor evaluation.

DOWNLOAD GUIDE

About Virta Health

Virta Health provides a nutrition-first, virtual-care approach to sustainable weight loss and metabolic health. Its model combines personalized nutrition, technology, health coaching, and provider-led clinical care.

According to the company, Virta works with more than 700 organizations and has provided over 200,000 members with access to its metabolic disease reversal services. Virta’s programs are designed to support eligible members living with obesity, prediabetes, type 2 diabetes, and related metabolic conditions—with, without, or following the use of GLP-1 medications.

To learn more, visit Virta Health.

Research Disclosure and Educational Disclaimer

This white paper was produced by Virta Health and includes descriptions of Virta’s services, research, internal analyses, client experience, and reported clinical and financial outcomes. Some claims are based on peer-reviewed studies, while others rely on company analyses, actuarial models, projections, or testimonials. Readers should review the citations and methodology provided in the white paper and independently evaluate the applicability of its findings to their fund and member population.

LaborForce Media is sharing this resource for general educational and informational purposes. Its inclusion in the Research section does not constitute independent validation or endorsement of every claim, product, service, or conclusion presented.

This article and the accompanying white paper should not be considered medical, legal, fiduciary, or benefits-consulting advice. Health plan coverage and treatment decisions should be made in consultation with qualified medical providers, benefits professionals, legal counsel, consultants, and other appropriate advisors.